Eli Lilly introduces Ramiven (abemaciclib) in India EP News Bureau Nov 25, 2022 Abemaciclib is a CDK4/6 inhibitor which has now been approved for HR+ HER2 - node positive high-risk Early Breast Cancer (EBC)
